Incidence and risk factors for venous thromboembolism in gynecological cancer: the GOTIC-VTE trial

Yoshifumi Takahashi,Hiroyuki Fujiwara,Kouji Yamamoto,Satoshi Yamaguchi,Shoji Nagao,Masashi Takano,Morikazu Miyamoto,Kosei Hasegawa,Maiko Miwa,Toshiaki Yasuoka,Soichi Yamashita,Takashi Hirakawa,Tomonori Nagai,Yoshinobu Hamada,Masaya Uno,Mayuyo Mori-Uchino,Michitaka Ohwada,Akira Mitsuhashi,Toyomi Satoh,Keiichi Fujiwara,Mitsuaki Suzuki,on behalf of the GOTIC-VTE Trial Investigators
DOI: https://doi.org/10.1007/s11239-024-03055-1
2024-11-30
Journal of Thrombosis and Thrombolysis
Abstract:Real-world data on venous thromboembolism (VTE) in Japanese patients with gynecological cancer are lacking. The GOTIC-VTE trial aimed to evaluate the frequency of VTE-associated events and risk factors at the time of cancer diagnosis and during 1-year follow-up. From July 2017 to February 2019, patients with endometrial, cervical, ovarian, tubal, or peritoneal cancer who underwent VTE screening within 2 months before registration, were enrolled. Of the 1008 patients enrolled, 881 were included in the analysis set, 51 (5.8%) had VTE at the time of cancer diagnosis (baseline), 7 (0.8%) had symptomatic VTE, and the majority had asymptomatic VTE (n = 44; 5.0%). Patients with ovarian, tubal, or peritoneal cancer had a higher incidence of VTE (13.7%) than those with other cancer types. During the 1-year follow-up, 0.9% (n = 8) of the patients had symptomatic VTE, 3.5% (n = 31) had composite VTE (symptomatic VTE and incidental VTE requiring treatment), 0.2% (n = 2) had bleeding events, and 4.3% (n = 38) had all-cause death, all of which were significantly higher in the VTE group at baseline. In the multivariate analysis, chemotherapy was an independent risk factor for composite VTE during the 1-year follow-up (hazard ratio 3.85, 95% confidence interval 1.39–13.63, p = 0.018). Among gynecological cancers, VTE incidence is particularly high in ovarian, tubal, or peritoneal cancer, and patients undergoing chemotherapy should be cautioned against VTE occurrence during treatment.
cardiac & cardiovascular systems,peripheral vascular disease,hematology
What problem does this paper attempt to address?